Bruker has signed an agreement with U.K.-based Primer Design for Bruker-Hain Diagnostics to distribute the genesig real-time polymerase chain reaction (PCR) assay for the novel coronavirus.
The CE-IVD assay is designed for use on Bruker-Hain Diagnostics' GenoXtract (GXT) automated nucleic acid extraction devices with associated extraction kits, and it targets very high specificity for SARS-CoV-2, the virus implicated in the respiratory disease COVID-19. It is validated for respiratory samples (nasopharyngeal swabs, oropharyngeal swabs, and sputum) on commonly available laboratory thermocyclers. The kit includes all necessary reagents to produce up to 96 results in under two hours, according to the companies.
Primer Design, which is a subsidiary of Novacyt, has already begun shipments to Spain, France, Germany, and the U.K.